On October 2, 2026, Immunome, Inc. (the "Company") reported to have entered into Amendment No. 4 to License Agreement (the "Amendment") with Bristol-Myers Squibb Company ("BMS") to further amend the License Agreement, by and between BMS and the Company (as assignee of Ayala Pharmaceuticals, Inc.), dated as of November 29, 2017 (as amended, the "License Agreement"). The Amendment removes the Company’s obligation to make any milestone and royalty payments under the License Agreement and assigns to the Company patent rights related to varegacestat (formerly AL102) and AL101 that were previously licensed to the Company under the License Agreement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As consideration for the Amendment, the Company paid BMS $20.0 million in cash and issued 4,425,487 shares of the Company’s common stock (collectively, the "Amendment Consideration"). Following payment of the Amendment Consideration, the Company has no milestone, royalty or other payment obligations to BMS under the License Agreement or the Amendment.

Stock Issuance Agreement

Concurrently with the execution of the Amendment, the Company entered into a stock issuance agreement (the "Stock Issuance Agreement") with BMS, pursuant to which the Company issued 4,425,487 shares of the Company’s common stock (the "Shares"), as partial consideration for entering into the Amendment.

The Company has agreed to use its commercially reasonable efforts to (x) file a resale registration statement with the Securities and Exchange Commission (the "SEC") registering the Shares for resale by November 16, 2026 and (y) cause such resale registration statement to be declared effective as soon as practicable after the filing thereof but no later than 60 calendar days after the filing thereof or by 5 business days from when the Company is notified that the SEC will not review the resale registration statement or that it will not be subject to further review.

The Company has also agreed to, among other things, indemnify BMS, its affiliates, partners, members, officers, directors, agents and representatives from certain liabilities and pay all fees and expenses (excluding any legal fees of BMS, and any underwriting discounts and selling commissions) incident to the Company’s obligations under the Stock Issuance Agreement.

The foregoing summary of the Amendment is not complete and is qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K, the License Agreement, a copy of which was filed as Exhibit 10.1 to our Current Report on Form 8-K filed on March 26, 2024, the Amendment No. 2 to License Agreement, dated August 7, 2024, a copy of which was filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q filed on November 13, 2024, and Amendment No. 3 to License Agreement, dated March 27, 2026, a copy of which was filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on May 12, 2026. Additionally, the foregoing summary of the Stock Issuance Agreement is not complete and is qualified in its entirety by reference to the Stock Issuance Agreement, a copy of which is filed as Exhibit 4.1 to this Current Report on Form 8-K.

(Filing, Immunome, OCT 2, 2026, View Source [SID1234673176])

On October 2, 2026 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported that President and Chief Executive Officer Jonathan Cohen and Chief Financial Officer Alan Bergman will participate in the Maxim Growth Summit 2026, being held October 13 and 14, 2026 at the Hard Rock Hotel New York. The Summit’s healthcare program takes place Wednesday, October 14.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Cohen and Mr. Bergman will hold one-on-one meetings with institutional investors at the Summit and in additional meetings scheduled in New York that week.

Maxim Growth Summit 2026
Dates: October 13 and 14, 2026; healthcare program Wednesday, October 14
Location: Hard Rock Hotel New York, 159 West 48th Street, New York, NY 10036
Format: One-on-one investor meetings
Attendees: President and Chief Executive Officer Jonathan Cohen; Chief Financial Officer Alan Bergman
Conference Website: Click here

To schedule a one-on-one meeting with management at the Maxim Growth Summit or in New York that week, please contact your Maxim Group representative, email [email protected], or call Chris Tyson at (949) 491-8235.

(Press release, 20/20 GeneSystems, OCT 2, 2026, View Source [SID1234671256])

On October 2, 2026 MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, reported two poster presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting. The presentations address two distinct areas of cancer research: tumor-cell killing in checkpoint inhibitor–resistant colorectal cancer liver metastases and elimination of senescent tumor cells and fibroblasts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first presentation examines agenT-797 alone and in combination with botensilimab and balstilimab (BOT+BAL) in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases. This preclinical research supports the rationale for the ongoing Phase 2 trial at Scripps, led by Darren Sigal, M.D., evaluating the combination in patients with previously treated microsatellite-stable (MSS) metastatic colorectal cancer with liver metastases (NCT07550088).

The second examines native agenT-797 and engineered MiNK-215, a FAP-targeting CAR-iNKT cell therapy incorporating IL-15, in oncogenic in vitro models of senescent tumor cells and fibroblasts.

Together, the presentations highlight complementary opportunities for MiNK’s platform; addressing treatment-resistant cancer and targeting senescent cancer and stromal cells.

Poster Presentation Details

Title: Native and engineered allogenic invariant natural killer T (iNKT) cells eliminate senescent tumor cells and fibroblasts in oncogenic in vitro models
Presenter: Jing Fang, Ph.D., Postdoctoral Fellow in the laboratory of Jesús Gil, MRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.
Date: Friday, November 6, 2026
Times: 12:15–1:45 p.m.; 6:40–8:10 p.m. MST
Location: Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4–6
Poster No.: 177

Title: agenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases
Presenter: Shanmugarajan Krishnan, Ph.D., M.S., B.S.; Agenus Inc., Lexington, MA
Date: Saturday, November 7, 2026
Times: 12:15–1:45 p.m.; 6:40–8:10 p.m. MST
Location: Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4–6
Poster No.: 270

(Press release, MiNK Therapeutics, OCT 2, 2026, https://www.globenewswire.com/news-release/2026/10/02/3373825/0/en/mink-therapeutics-to-present-data-on-treatment-resistant-colorectal-cancer-and-clearance-of-senescent-tumor-cells-and-fibroblasts-at-sitc-2026.html [SID1234671255])

On October 2, 2026 Pyxis Oncology, Inc. (Nasdaq: PYXS or the "Company"), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, reported that it closed its previously announced registered public offering (the "Offering") on October 1, 2026. The Offering generated approximately $110.0 million in upfront gross proceeds, before deducting underwriting discounts and commissions and other offering expenses. The Offering consisted of 36,047,919 shares of common stock at a public offering price of $2.90 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,883,121 shares of common stock at a public offering price of $2.899 per pre-funded warrant, in each case, accompanied by common warrants to purchase an aggregate of 49,310,352 shares of common stock.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical milestone-linked common warrants are tied to Pyxis Oncology’s public disclosure of overall survival data (the "OS Data Release Date") from its ongoing Phase 1 monotherapy study of micvotabart pelidotin ("MICVO") in second-line and beyond ("2L+") recurrent/metastatic head and neck squamous cell carcinoma ("R/M HNSCC"), which is expected to occur in the first half of 2027. The warrants have an exercise price of $3.50 per common share, a 21% premium to the $2.90 public offering price. If all milestone-linked warrants are exercised in full for cash, the Offering would provide Pyxis Oncology with approximately $172.6 million in additional gross proceeds, for a total of approximately $282.6 million in gross proceeds, before deducting applicable expenses.

The common warrants will become exercisable only upon approval by the Company’s stockholders of an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of common stock and the effectiveness of that amendment (the date of such effectiveness, the "Charter Amendment Effective Date"), and will expire upon the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of (x) the Charter Amendment Effective Date and (y) the OS Data Release Date.

The Offering included participation from new and existing institutional investors, including OrbiMed, GordonMD Global Investments, BVF Partners, Coastlands Capital, and RTW Investments.

Leerink Partners, Guggenheim Securities and Wells Fargo Securities acted as joint bookrunning managers for the Offering.

Pyxis Oncology intends to use the net proceeds from the Offering to advance its lead clinical program, MICVO, through key clinical milestones, including Headliner, its planned Phase 3 trial in 2L+ R/M HNSCC, and for working capital and general corporate purposes. The Company also plans to disclose updated data from its ongoing Phase 1/2 combination dose escalation study of MICVO and Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy KEYTRUDA (pembrolizumab) for first-line (1L) R/M HNSCC patients in the fourth quarter of 2026.

(Press release, Pyxis Oncology, OCT 2, 2026, View Source [SID1234671254])

On October 2, 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, reported that data from the Company’s lapemelanotide zapixetar (also known as [²¹²Pb]VMT01) program have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting & Pre-Conference Programs taking place November 4 to 8, 2026, in Phoenix, Arizona. SITC (Free SITC Whitepaper) plans to release further details for regular abstracts on November 3, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presenting Author Abstract Title Presentation Details
Matthew Block, Department of Oncology, Mayo Clinic
A phase I/IIa trial of [212Pb]VMT01 MC1R-targeted alpha-particle mono- and combination-therapy with nivolumab in participants with previously treated unresectable or metastatic melanoma Abstract Number: 571
Presentation type: Poster presentation
Date: Friday, Nov. 6, 2026
Location: PCC-North Building-Lower Level-Exhibition Halls
4-5-6

About [²¹²Pb]VMT-01

Perspective designed [212Pb]VMT01 to target and deliver 212Pb to metastatic melanoma tumor sites expressing MC1R, a protein that can be overexpressed in metastatic melanoma tumors.1 The Company is conducting a multi-center, open-label dose escalation, dose expansion study (clinicaltrials.gov identifier NCT05655312) in patients with histologically confirmed melanoma and MC1R-positive imaging scans.

Interim analysis with a data cut-off date of March 25, 2026 was presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in May 2026. Highlights from the ASCO (Free ASCO Whitepaper) analysis included the following:

Patients were heavily pre-treated prior to entering trial with a median of 4 prior lines of systemic therapy (including prior checkpoint inhibitors)

One new response was observed early in the 3.0 mCi monotherapy cohort, in addition to a previously reported response, for a total of two responders out of seven treated patients

Six patients (86%) experienced stable disease or partial response out of the seven patients in the 3.0 mCi monotherapy cohort; four patients completed all three treatments with 24 weeks or more of follow-up since their first treatment, and two remained on treatment and in study
[²¹²Pb]VMT01 was well-tolerated with no dose limiting toxicities (DLTs), no discontinuations due to adverse events, and no Grade 4 or Grade 5 treatment emergent adverse events (TEAEs)
Eight (30%) patients out of a total of 27 patients treated experienced Grade 3 TEAEs

(Press release, Perspective Therapeutics, OCT 2, 2026, View Source [SID1234671253])